We advised CStone Pharmaceuticals on the placement

Davis Polk advised CStone Pharmaceuticals in its placement of 84,800,000 new shares, for an aggregate consideration of approximately HK$392.9 million.

Davis Polk also advised CStone Pharmaceuticals in its HK$2.24 billion IPO in February 2019.

CStone Pharmaceuticals is a biopharmaceutical company focused on research, development and commercialization of innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Since the company’s establishment, the company has assembled a world-class management team with extensive experience in innovative drug development, clinical research and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies.

The Davis Polk team included partner Yang Chu and associates Yue (Jenny) Yin and Yi Kai Sit. Members of the Davis Polk team are based in Hong Kong and Beijing offices.

Copy link to share post